WAKAMOTO PHARMACEUTICAL CO.,LTD. Logo

WAKAMOTO PHARMACEUTICAL CO.,LTD.

Develops gastrointestinal and ophthalmic drugs for the health challenges of an aging society.

4512 | T

Overview

Corporate Details

ISIN(s):
JP3991200001
LEI:
Country:
Japan
Address:
中央区日本橋本町二丁目2番2号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Wakamoto Pharmaceutical Co., Ltd. is a research-driven pharmaceutical company engaged in the development, manufacturing, and sale of prescription (ethical) and over-the-counter (OTC) medicines. The company specializes in two primary therapeutic areas: gastroenterology and ophthalmology. Its product portfolio includes the well-known gastrointestinal drug "Strong Wakamoto," which utilizes a proprietary microorganism to produce digestive enzymes, and a range of ophthalmic solutions for treating eye disorders. Wakamoto Pharmaceutical focuses its research and development efforts on creating medications and medical equipment to address the health challenges of an aging society.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 08:03
Registration Form
確認書
Japanese 8.1 KB
2025-11-13 08:03
Interim Report
半期報告書-第131期(2025/04/01-2026/03/31)
Japanese 182.0 KB
2025-06-27 10:03
Post-Annual General Meeting Information
臨時報告書
Japanese 24.7 KB
2025-06-20 08:53
Governance Information
内部統制報告書-第130期(2024/04/01-2025/03/31)
Japanese 21.5 KB
2025-06-20 08:51
Registration Form
確認書
Japanese 8.1 KB
2025-06-20 08:48
Annual Report
有価証券報告書-第130期(2024/04/01-2025/03/31)
Japanese 1014.1 KB
2025-02-06 08:28
Major Shareholding Notification
臨時報告書
Japanese 19.3 KB
2024-11-13 01:51
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-11-13 01:46
Interim Report
半期報告書-第130期(2024/04/01-2025/03/31)
Japanese 183.5 KB
2024-07-02 05:00
Post-Annual General Meeting Information
臨時報告書
Japanese 33.6 KB
2024-06-28 08:24
Governance Information
内部統制報告書-第129期(2023/04/01-2024/03/31)
Japanese 21.7 KB
2024-06-28 08:21
Registration Form
確認書
Japanese 8.1 KB
2024-06-28 08:19
Annual Report
有価証券報告書-第129期(2023/04/01-2024/03/31)
Japanese 1007.9 KB
2024-02-14 01:17
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-02-14 01:17
Quarterly Report
四半期報告書-第129期第3四半期(2023/10/01-2023/12/31)
Japanese 155.8 KB

Automate Your Workflow. Get a real-time feed of all WAKAMOTO PHARMACEUTICAL CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for WAKAMOTO PHARMACEUTICAL CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for WAKAMOTO PHARMACEUTICAL CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Medios AG Logo
Compounding patient-specific therapies and supplying specialty pharma for complex conditions.
Germany
ILM1
Develops cord blood stem cell therapies for osteoarthritis & infant lung disease, plus banking.
South Korea
078160
MediWound Ltd. Logo
Develops enzymatic therapies for non-surgical tissue repair in burns and chronic wounds.
United States of America
MDWD
Medizen Humancare Inc Co., Ltd Logo
Offers DTC genetic testing and genomic analysis for personalized disease risk prediction.
South Korea
236340
Medy-Tox Inc. Logo
Develops and markets botulinum toxins and dermal fillers for global aesthetic & therapeutic use.
South Korea
086900
MeiraGTx Holdings plc Logo
Develops genetic medicines for eye, salivary gland, and CNS disorders using gene regulation tech.
United States of America
MGTX
Meito  Sangyo  Co., Ltd. Logo
Produces food products and specialty chemicals for industrial and pharmaceutical applications.
Japan
2207
Merck & Co., Inc. Logo
A global biopharma developing innovative medicines, vaccines, and animal health products.
United States of America
MRK
Mereo BioPharma Group plc Logo
A clinical-stage biopharma developing and commercializing novel therapies for rare diseases.
United States of America
MREO
Mersana Therapeutics, Inc. Logo
Developing innovative antibody-drug conjugates using proprietary platforms to treat cancer.
United States of America
MRSN

Talk to a Data Expert

Have a question? We'll get back to you promptly.